Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone

被引:175
作者
Anker, SD
Volterrani, M
Pflaum, CD
Strasburger, CJ
Osterziel, KJ
Doehner, W
Ranke, MB
Poole-Wilson, PA
Giustina, A
Dietz, R
Coats, AJS
机构
[1] Salvatore Maugeri Fdn, Dept Cardiol, Gussago, Italy
[2] Univ Munich, Med Klin, Munich, Germany
[3] Univ Tubingen, Kinderklin, Sekt Padiatr Endokrinol, Tubingen, Germany
[4] Univ Brescia, Dept Internal Med, Endocrine Sect, Brescia, Italy
[5] Franz Volhard Klin, Charite, Berlin, Germany
[6] Max Delbruck Ctr Mol Med, Charite, Berlin, Germany
关键词
D O I
10.1016/S0735-1097(01)01385-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We aimed to determine whether growth hormone (GH) resistance is present in patients with chronic heart failure (CHF) and whether it may be linked to the biochemical response to GH treatment. Background Acquired GH resistance is a feature of severe illness, in particular, cachexia. In patients with CHF, the response to GH therapy appears to be variable. Methods Biochemical markers of the GH-insulin-like growth factor-I (IGF-I) axis were compared in 21 cachectic patients with CHF, 51 noncachectic patients and 26 healthy control subjects. In separate studies, the predictive value of baseline biochemical variables for the IGF-I response to GH treatment was analyzed. Results Cachectic patients showed an increase of total GH and immunologically intact GH (p less than or equal to 0.0002) and a decrease of GH-binding protein (BP) (p = 0.005), IGF-BP3 (p = 0.01) and IGF-I (p = 0.06), compared with noncachectic patients. Similar changes were found when the cachectic group was compared with the control group. No differences were found between noncachcctic patients and control subjects. Levels of GH-BP correlated with the IGF-UGH ratio in all subgroups (all p less than or equal to 0.002). Baseline GH-BP levels were related to the increase of IGF-I levels in response to GH treatment in patients with CHF after 24 h (r = 0.83, p = 0.005; n = 9; study 2), 44 days (r = 0.52, p = 0.007; n = 25; study 3) and 96 days (r = 0.54, p = 0.006; n = 24; study 3). Conclusions Most cachectic and some noncachectic patients with CHF show features of acquired GH resistance. The principal predictors of the biochemical features of GH resistance and of the poor biochemical response to short-term and longer-term GH treatment are GH-BP plasma levels. The presence of GH resistance is potentially a major factor determining the response to GH therapy in patients with CHF. (J Am Coll Cardiol 2001;38:443-52) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:443 / 452
页数:10
相关论文
共 44 条
[1]  
Anker SD, 1997, EUR HEART J, V18, P259
[2]   Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure [J].
Anker, SD ;
Ponikowski, PP ;
Clark, AL ;
Leyva, F ;
Rauchhaus, M ;
Kemp, M ;
Teixeira, MM ;
Hellewell, PG ;
Hooper, J ;
Poole-Wilson, PA ;
Coats, AJS .
EUROPEAN HEART JOURNAL, 1999, 20 (09) :683-693
[3]   Cardiac cachexia - A syndrome with impaired survival and immune and neuroendocrine activation [J].
Anker, SD ;
Coats, AJS .
CHEST, 1999, 115 (03) :836-847
[4]   Wasting as independent risk factor for mortality in chronic heart failure [J].
Anker, SD ;
Ponikowski, P ;
Varney, S ;
Chua, TP ;
Clark, AL ;
WebbPeploe, KM ;
Harrington, D ;
Kox, WJ ;
PooleWilson, PA ;
Coats, AJS .
LANCET, 1997, 349 (9058) :1050-1053
[5]  
Anker SD, 1997, CIRCULATION, V96, P526
[6]   Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and decompensated liver cirrhosis [J].
Assy, N ;
Hochberg, Z ;
Enat, R ;
Baruch, Y .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (06) :1317-1321
[7]   Cardiovascular effects of GH [J].
Bengtsson, BA ;
Christiansen, JS ;
Cuneo, RC ;
Sacca, L .
JOURNAL OF ENDOCRINOLOGY, 1997, 152 (01) :1-3
[8]   ACQUIRED GROWTH-HORMONE RESISTANCE IN PATIENTS WITH HYPERCATABOLISM [J].
BENTHAM, J ;
RODRIGUEZARNAO, J ;
ROSS, RJM .
HORMONE RESEARCH, 1993, 40 (1-3) :87-91
[9]  
Blum W., 1996, DIAGNOSTICS ENDOCRIN, P190
[10]  
BLUM WF, 1997, GROWTH REGULAT, V7, P11